Version: 1.0.0 | Published: 31 Aug 2026 | Updated: 1 day ago
Documentation
Associated Media:
Description:
The aim of this study is to assess the technical feasibility of delivering radical radiotherapy for prostate cancer using the MR-Linac, including the feasibility of changing the radiotherapy plan on a daily basis to mirror internal anatomy changes.
Standard radiotherapy for prostate cancer is directed using scans or X-Rays, which ensures the radiotherapy treatment "hits the target" and avoids the healthy tissues around the prostate. There are two current methods of radiotherapy image guidance- either placing small gold seeds into the prostate and taking XRays or doing a small CT scan of the prostate region each day. Neither of these methods are perfect and have drawbacks and inaccuracies.
The best way to see the prostate is with an MRI scan - this shows the edge of the prostate much more clearly and can even show the area of most aggressive cancer within the prostate.
The new MR-Linac machine combines an MR scanner and a radiotherapy machine, allowing the investigators to keep watching the prostate while the patient has their treatment. The new machine also gives a clearer image and so will allow the investigators to change the radiotherapy plan if the internal anatomy can be seen to have shifted.
The team delivered the same dose in the same number of days as standard radiotherapy, and recorded the length of time required for patients to have their MR guided adaptive radiotherapy for each fraction - to inform whether treatment can be given in a clinically feasible time frame, using the new technique/machine.
Side effects were assessed by physicians and using patient questionnaires.
Coverage
Spatial:
Sutton LB, United Kingdom
Typical Age Range:
18-150
Follow Up:
0 - 6 Months
Pathway:
Recruited 28 patients with localised prostate cancer who needed radiotherapy.
The same dose of radiotherapy delivered in the same number of days as standard
radiotherapy, but using MR-Linac - with option of changing radiotherapy plan on
a daily basis to mirror internal anatomy changes. Side effects assessed by
physicians and using patient questionnaires.
Provenance
Origin
Purposes:
Study
Sources:
- Other
- Machine generated
Collection Situations:
Cohort, study, trial
Temporal
Accrual Periodicity:
Static
Start Date:
07 August 2018
End Date:
10 June 2025
Time Lag:
Not applicable
Accessibility
Access
Access Rights:
in progress
Access Service:
Although not required, there is an option to use The Royal Marsden’s Trusted
Research Environment and informatics platform: BRIDgE (Biomedical Research
Informatics Digital Environment). BRIDgE is managed by The Royal Marsden’s
Information Team with support by the NIHR Biomedical Research Centre at The
Royal Marsden and ICR. The aim of the platform is to transform clinical practice
and improve outcomes for patients by enabling researchers to access real-world
cancer data within secure, collaborative, cloud-based workspaces. Learn more by
visiting the BRIDgE site within the NIHR BRC area of The Royal Marsden and ICR
website: https://www.cancerbrc.org/BRIDgE
Access Request Cost:
Depends on type of access. Costing available on application.
Delivery Lead Time:
Variable
Jurisdictions:
UK
Data Controller:
Royal Marsden NHS Foundation Trust
Data Processor:
Royal Marsden NHS Foundation Trust
Usage
Data Use Limitations:
Research-specific restrictions
Data Use Requirements:
- Ethics approval required
- Institution-specific restrictions
- User-specific restriction
- Not for profit use
Resource Creators:
The Royal Marsden NHS Foundation Trust; The Royal Marsden Cancer Charity; NIHR Biomedical Research Centre at The Royal Marsden and the ICR; Cancer Research UK
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Conforms To:
LOCAL
Languages:
en